Cyclosporine nephrotoxicity: Implications for dermatology

International Journal of Dermatology

Volumn 36, Issue SUPPL. 1, 1997, Pages 11-14

  Bennett, William M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; DIURETIC AGENT; FELODIPINE; IMMUNOSUPPRESSIVE AGENT; ISRADIPINE; NIFEDIPINE; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CONFERENCE PAPER; DRUG EFFECT; DRUG FORMULATION; DRUG INDUCED DISEASE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; NEPHROTOXICITY; PATIENT MONITORING; PRACTICE GUIDELINE; PSORIASIS; SKIN DISEASE;

EID: 0031445831     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.36.s1.1.x     Document Type: Conference Paper

References (20)

1. Tredger JM. Using cyclosporine Neoral immediately after liver transplantation. Ther Drug Monit 1995; 17: 638-641.
2. Johnston A, Reynold L, Wright DL, et al. Pharmacokinetics of cyclosporin in heart transplant patients after administration of Sandimmune and a new oral formulation Neoral. Ther Drug Monit 1995; 17: 415.
3. Klauser R, Irschik H, Kletzmayer J, et al. Neoral: a new microemulsion formula of cyclosporine A. Interpatient pharmacokinetic variability in renal transplant patients. Transplant Proc 1995; 27: 3427-3429.
4. Yee GC, Salomen DR. Applied pharmacokinetics. Principles of therapeutic drug monitoring. In: Evans WE, Shentag JJ, Jusko WJ, eds. Cyclosporine. Vancouver: Applied Therapeutics, 1992; 1-40.
5. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738.
6. Kovarik JM, Meuller EA, Johnston A, et al. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy 1993; 13: 613-617.
7. Freeman D, Grant D, Levy G, et al. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. Ther Drug Monit 1995; 17: 213-216.
8. Kovarik JM, Meuller EA, van Bree JB, et al. Within-day consistence in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994; 16: 232-237.
9. Barone G, Chang CT, Choc MG, et al. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. Transplantation 1996; 61: 875-880.
10. Kovarik JM, Meuller EA, van Bree JB, et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83: 444-446.
11. Kovarik JM, Meuller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion. A multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658-663.
12. Kovarik JM, Meuller EA, van Bree JB, et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients. A concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57: 1178-1182.
13. English J, Evan A, Houghton DC, et al. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44: 135-141.
14. Ruggententi P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706-711.
15. Curtis JJ, Luke RG, Dubosky E, et al. Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; 2: 477-479.
16. Burdmann EA, Andoh TF, Nast CC, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491-F499.
17. Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-1100.
18. Bennett WM, DeMattos A, Norman DJ. Which cyclosporin formulation? Lancet 1996; 348: 205.
19. Bunke M, Sloan R, Brier M, et al. An improved glomerular filtration rate in cardiac transplant recipients with once-a-day cyclosporine dosing. Transplantation 1995; 59: 537-540.
20. McNally PG, Walls J, Feehally J. The effect of nifedipine on renal function in normotensive cyclosporin-A-treated renal allograft recipients. Nephrol Dial Transplant 1990; 5: 962-968.